Tirzepatide – Kodiac biolabs

Plain-language summaryIntrigue 93 / 100

Tirzepatide, sold as Mounjaro and Zepbound, is the first dual GLP-1 and GIP receptor agonist. By activating both incretin receptors, it produces more weight loss than semaglutide in head-to-head trials. Approved by the FDA in 2022. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

80/100

Dual incretins done right: the FDA-approved benchmark that defines what GIP/GLP-1 co-agonism can achieve

Look, tirzepatide isn’t just another incretin. The whole story starts at the receptor pharmacology: GIP and GLP-1 agonism together produce a genuinely additive effect that neither receptor achieves alone. GIP engagement modulates adipose tissue metabolism and potentiates insulin secretion in a glucose-dependent fashion; GLP-1 handles central satiety signaling, gastric emptying delay, and glucagon suppression. Running both pathways simultaneously turns out to be more than the sum of its parts, and the SURMOUNT program is the evidence base that confirmed it at scale.

SURMOUNT-1, published in the New England Journal of Medicine in 2022, showed average weight loss of 20.9% at the 15 mg weekly dose in adults with obesity over 72 weeks, with N above 2500. These arent modest numbers from a single lab. SURMOUNT-2, -3, and -4 extended the findings to T2DM populations, confirmed durability after withdrawal, and locked in the dose-response relationship. Multiple RCTs, multiple populations, consistent signal. The evidence quality here is genuinely high for a peptide compound.

What we find most interesting from a research standpoint is what the GIP component actually contributes. GLP-1 monotherapy was already well-validated before tirzepatide arrived. In a real sense, tirzepatide is the controlled experiment for what layering GIP receptor agonism adds on top of established GLP-1 biology. The GIP receptor’s role in adipose tissue, its interactions with adiponectin signaling, and the downstream effects on fat mass independent of energy intake are not fully characterized, and tirzepatide is one of the few available probes for studying that biology at clinically meaningful concentrations.

We dont think it’s breaking news anymore, though. Tirzepatide is FDA-approved, widely prescribed, and the research program is maturing fast. Novelty has a shelf life, and this compound is burning through it. Retatrutide is already in phase 2 with a triple agonist profile adding glucagon receptor activity, which makes tirzepatide look like a stepping stone in a rapidly evolving pharmacology story. Bench investigators focused purely on incretin frontier biology will want to be watching that space closely.

For investigators working on metabolic pharmacology, incretin receptor biology, adipose tissue signaling, or GLP-related satiety circuitry, tirzepatide remains one of the most useful tools available. The evidence base is unusually clean. The mechanism is well-defined. And the gap it opened between dual and single GLP-1 agonism is exactly the kind of differentiated signal that gives a research program somewhere real to go. The score reflects a compound that genuinely moved the field, even as the field is already starting to move past it.

Novelty: 72
Mechanism promise: 85
In-category differentiation: 80
Evidence quality: 87
Translational signal: 88
Research bench value: 68

Rationale Tirzepatide scores high on mechanism promise and evidence quality because the SURMOUNT trial program is unusually clean and large for a peptide this young, and the dual-receptor pharmacology is genuinely differentiated from GLP-1 monotherapy. Novelty is real but moderating now that it’s an approved, widely-prescribed agent; retatrutide’s emergence makes tirzepatide look increasingly like the floor of what’s possible in this class rather than the ceiling.

GIP/GLP-1 dual receptor agonist

A dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023), producing greater weight loss than GLP-1-only agents.

Abstract

Tirzepatide (Mounjaro, Zepbound; CAS 2023788-19-2; molecular weight 4813.54) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist developed by Eli Lilly and approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). The compound is a 39-amino-acid synthetic peptide based on the GIP scaffold with modifications at positions enabling GLP-1 receptor agonism alongside GIP receptor activity. Mechanism is dual GIP/GLP-1 receptor agonism producing complementary effects: GIP engagement adds to GLP-1’s glucose-dependent insulin secretion and contributes to weight regulation through fat metabolism modulation; GLP-1 contributes the central satiety, gastric emptying, and glucagon suppression effects. The combination produces substantially greater weight loss than GLP-1 monotherapy: SURMOUNT trials showed 15 to 22 percent weight loss over 72 weeks at 5 to 15 mg weekly doses. Approved doses titrate to 5, 10, or 15 mg per week subcutaneous.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-083Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.